Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance
Liver cancer ranks as the sixth most prevalent malignancy globally, with Hepatocellular Carcinoma (HCC) constituting the predominant subtype, thereby imposing a significant burden on public health and presenting limited therapeutic options. Despite ongoing efforts to innovate treatment modalities, a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1595195/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218997595766784 |
|---|---|
| author | Hongtao Zhang Hongtao Zhang Zhaoming Yang Zhengwu Jiang Zhijian Zhao Xun Chen Xun Chen Jian Wan Jian Wan Yukun Li |
| author_facet | Hongtao Zhang Hongtao Zhang Zhaoming Yang Zhengwu Jiang Zhijian Zhao Xun Chen Xun Chen Jian Wan Jian Wan Yukun Li |
| author_sort | Hongtao Zhang |
| collection | DOAJ |
| description | Liver cancer ranks as the sixth most prevalent malignancy globally, with Hepatocellular Carcinoma (HCC) constituting the predominant subtype, thereby imposing a significant burden on public health and presenting limited therapeutic options. Despite ongoing efforts to innovate treatment modalities, anti-angiogenesis therapy continues to be the primary strategy for managing HCC. Angiogenesis is a pivotal process within the tumor microenvironment, characterized by the formation of new blood vessels that provide essential nutrients and oxygen to proliferating tumors, thereby facilitating their growth and potential metastasis. Numerous angiogenic signaling pathways become dysregulated during this process. Targeting these aberrant pathways can yield significant therapeutic benefits for patients and may even reverse drug resistance. However, these signaling pathways frequently demonstrate intricate crosstalk and interconnections. Elucidating these interactions could represent a crucial strategy for advancing the treatment of HCC. This review provides both mechanistic insights into angiogenic network plasticity and translational strategies to overcome therapeutic bottlenecks in HCC management. |
| format | Article |
| id | doaj-art-2c7aecf367594e66b4a513feb33d8e7d |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-2c7aecf367594e66b4a513feb33d8e7d2025-08-20T02:07:31ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15951951595195Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistanceHongtao Zhang0Hongtao Zhang1Zhaoming Yang2Zhengwu Jiang3Zhijian Zhao4Xun Chen5Xun Chen6Jian Wan7Jian Wan8Yukun Li9Jishou University Zhuzhou Clinical College, Medical College, Jishou University, Zhuzhou, Hunan, ChinaSecond Department of Hepatobiliary Pancreatic and Splenic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, ChinaSecond Department of Hepatobiliary Pancreatic and Splenic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, ChinaSecond Department of Hepatobiliary Pancreatic and Splenic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, ChinaSecond Department of Hepatobiliary Pancreatic and Splenic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, ChinaJishou University Zhuzhou Clinical College, Medical College, Jishou University, Zhuzhou, Hunan, ChinaSecond Department of Hepatobiliary Pancreatic and Splenic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, ChinaJishou University Zhuzhou Clinical College, Medical College, Jishou University, Zhuzhou, Hunan, ChinaSecond Department of Hepatobiliary Pancreatic and Splenic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, ChinaDepartment of Assisted Reproductive Center, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, ChinaLiver cancer ranks as the sixth most prevalent malignancy globally, with Hepatocellular Carcinoma (HCC) constituting the predominant subtype, thereby imposing a significant burden on public health and presenting limited therapeutic options. Despite ongoing efforts to innovate treatment modalities, anti-angiogenesis therapy continues to be the primary strategy for managing HCC. Angiogenesis is a pivotal process within the tumor microenvironment, characterized by the formation of new blood vessels that provide essential nutrients and oxygen to proliferating tumors, thereby facilitating their growth and potential metastasis. Numerous angiogenic signaling pathways become dysregulated during this process. Targeting these aberrant pathways can yield significant therapeutic benefits for patients and may even reverse drug resistance. However, these signaling pathways frequently demonstrate intricate crosstalk and interconnections. Elucidating these interactions could represent a crucial strategy for advancing the treatment of HCC. This review provides both mechanistic insights into angiogenic network plasticity and translational strategies to overcome therapeutic bottlenecks in HCC management.https://www.frontiersin.org/articles/10.3389/fonc.2025.1595195/fullhepatocellular carcinomaangiogenesisinhibitorpathwaysdrug resistance |
| spellingShingle | Hongtao Zhang Hongtao Zhang Zhaoming Yang Zhengwu Jiang Zhijian Zhao Xun Chen Xun Chen Jian Wan Jian Wan Yukun Li Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance Frontiers in Oncology hepatocellular carcinoma angiogenesis inhibitor pathways drug resistance |
| title | Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance |
| title_full | Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance |
| title_fullStr | Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance |
| title_full_unstemmed | Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance |
| title_short | Aberrant angiogenic signaling in HCC: therapeutic targeting and drug resistance |
| title_sort | aberrant angiogenic signaling in hcc therapeutic targeting and drug resistance |
| topic | hepatocellular carcinoma angiogenesis inhibitor pathways drug resistance |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1595195/full |
| work_keys_str_mv | AT hongtaozhang aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance AT hongtaozhang aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance AT zhaomingyang aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance AT zhengwujiang aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance AT zhijianzhao aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance AT xunchen aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance AT xunchen aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance AT jianwan aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance AT jianwan aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance AT yukunli aberrantangiogenicsignalinginhcctherapeutictargetinganddrugresistance |